Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 5/20 | 0.67 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 2/20 | 0.49 |
| ▸ | DTYMK | P23919 | 4/20 | 0.47 |
| ▸ | POLG | P54098 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701817 | 0.91 | POLB (0.69) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL24219865 | 0.90 | POLB (0.71) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29948896 | 0.89 | POLB (0.70) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL22053474 | 0.88 | POLB (0.67) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL22053473 | 0.88 | POLB (0.67) | P2RY2P2RY4P2RY6POLBFUT5 | |
| Deoxyguanosine SCHEMBL20445785 | 0.86 | POLB (0.67) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29365434 | 0.86 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29371610 | 0.86 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL4078522 | 0.86 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29702417 | 0.86 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | PROTERA S.R.L. (IT) | 2008-12-04 | — | — | US | claimed |
| EP-1778254-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | Protera S.R.L. (IT) | 2007-05-02 | — | — | EP | claimed |
| WO-2006013203-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | PROTERA S.R.L. (IT) | 2006-02-09 | — | — | WO | claimed |
| US-8110676-B2 | Prodrugs activated by RNA-dependent DNA-polymerases | PROTERA S.R.L. (IT) | 2012-02-07 | — | — | US | disclosed |
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | PROTERA S.R.L. (IT) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | TERT, POLRMT, POLI | P2RY2 2889/4885P2RY4 2488/4885P2RY6 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.